Page 13 - Cipla

Spiralling demand, leakages and a flourishing black market for remdesivir

Artificial shortages and brazen hawking of the drug on the streets at 15x the normal price rule the day as the official machinery tries desparately to stamp out the parallel market

Covid-19: Govt waives import duty on Remdesivir injection, raw materials

Given the shortage of supplies, the Union government last week banned the export of Remdesivir

Chhattisgarh may sue Cipla for not meeting remdesivir supply requirements

According to Singh Deo, the Indian pharma major had reneged on the contract signed on April 3 to supply Remdesivir injections to the state

US respiratory portfolio to drive medium term sales growth for Cipla

In the domestic market, growth is expected to come from Covid-related drugs

Covid-19: Jharkhand seeks Centre's nod to import Remdesivir from Bangladesh

Jharkhand government sought permission from the Centre to import 50,000 vials of the Covid-19 drug from a Bangladeshi pharmaceuticals company

Cipla doubles remdesivir production to meet 'unprecedented' demand

Just two months ago, Cipla had projected falling demand for remdesivir in India as coronavirus infections were on a steady decline.

Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs

Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade

Cipla board approves reappointment of Umang Vohra as MD & Global CEO

Pharma major Cipla on Tuesday said its board hasapproved the re-appointment of Umang Vohra as the Managing Director and Global CEO of the company for a further period of five years. The board of directorshas considered and approved the re-appointment ofUmang Vohra, Managing Director, designated as 'Managing Director and Global Chief ExecutiveOfficer' of the company, for a further period of five years w.e.f. April 1, 2021 to March 31,2026, Cipla said in a regulatory filing. Vohra had joined Cipla in 2015 and has been the MD & Global CEO of the company since September 1, 2016, it added. "As Cipla's MD & GCEO, Vohra's priorities have been Cipla's strategic growth, defining and executing Cipla's roadmap to maintain momentum in home markets whilst strengthening its presence in other regions, consolidating its core focus areas, augmenting capability, and building the right organisation," the filing said. After gaining degrees in engineering, marketing and finance, Vohraworked with ..

Cipla liquidates wholly-owned unit as part of internal reorganisation

Drug major Cipla on Saturday said it has voluntarily liquidated a wholly-owned step-down subsidiary.

Cipla's Gulf arm to sell 4 biosimilar medicines in Australia, New Zealand

Cipla stock went up by almost 3 per cent on Tuesday

Cipla's Gulf arm to sell 4 biosimilar medicines in Australia, New Zealand

Cipla Gulf will be responsible for commercialisation of patented biosimilars of the biologic medicine brands -- Aflibercept, Ustekimumab,Denosumab and Golimumab.

Cipla receives USFDA nod for nasal spray for treating migraine attacks

Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Sumatriptan Nasal Spray, indicated for the treatment of migraine attacks

Cipla plans to double share from consumer health business in 5 years

Transitioning brands from prescription and trade generics to over-the-counter

Domestic drug market growth slows top 4.5% in January, some therapies drag

Respiratory segment and anti-infectives contract; Cardiac, anti-diabetic growth rates plummet

Nifty Pharma index surges 4%; Sun Pharma, Cipla hit 52-week highs

At 12:57 pm, Nifty Pharma index, the top gainer among sectoral indices, was up 4.2 per cent, as compared to 1.3 per cent gain in the benchmark Nifty50 index

Cipla's net profit zooms 113% in December quarter; revenue up 18%

The total revenue from operations came in at Rs 5,169 crore and the net profit stood at Rs 748 crore, up 113 per cent.

Stocks to watch: TCS, Wipro, Avenue Supermarts, Tata Steel, Vedanta, Cipla

Bharti Airtel announced the appointment of Pradipt Kapoor as its Chief Information Officer

Bright outlook: Sun Pharma to Cipla, drug firms set for Q3 health boost

Analysts expect earnings growth to be in the range of 30-40 per cent for drug firms owing to both domestic recovery as well as strong export opportunities

Cipla recalls over 5.8 lakh packets of gastric ulcer treatment drug in US

Drug major Cipla is recalling over 5.8 lakh packets of a drug for the reduction in the occurrence of gastric ulcers from the US market, as per a report by the US Food and Drug Administration.

Trading calls by Ajit Mishra of Religare Broking: Buy Cipla, Eicher Motors

Eicher Motors' stock has been witnessing profit taking for the last one month, and is likely to see a gradual recovery from hereon